Poly Medicure Ltd
NSE:POLYMED

Watchlist Manager
Poly Medicure Ltd Logo
Poly Medicure Ltd
NSE:POLYMED
Watchlist
Price: 2 826.2 INR 1.83% Market Closed
Market Cap: 286.4B INR
Have any thoughts about
Poly Medicure Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one POLYMED stock under the Base Case scenario is 2 106.29 INR. Compared to the current market price of 2 826.2 INR, Poly Medicure Ltd is Overvalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

POLYMED Relative Value
Base Case
2 106.29 INR
Overvaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

18.8
P/S
P/S
Price to Sales
18.8
vs History
1
vs Industry
10
Median 3Y
10.4
Median 5Y
9.3
Industry
2.3
Forward
16.5
More Details
97.1
P/E
P/E
Price to Earnings
97.1
vs History
1
vs Industry
5
Median 3Y
61
Median 5Y
57.5
Industry
23
Forward
81.2
More Details
113.3
P/OCF
P/OCF
Price to OCF
113.3
vs History
6
vs Industry
3
Median 3Y
61.4
Median 5Y
59.2
Industry
14.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
100
Median 3Y
-196.1
Median 5Y
-166.3
Industry
20
More Details
11
P/B
P/B
Price to Book Value
11
vs History
12
vs Industry
4
Median 3Y
9.2
Median 5Y
8.6
Industry
2.2
More Details
18
EV/S
EV/S
Enterprise Value to Sales
18
vs History
1
vs Industry
10
Median 3Y
10.1
Median 5Y
9.1
Industry
2.4
Forward
15.8
More Details
27
EV/GP
EV/GP
Enterprise Value to Gross Profit
27
vs History
1
vs Industry
8
Median 3Y
16.3
Median 5Y
14.9
Industry
5
More Details
67.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
67.4
vs History
1
vs Industry
4
Median 3Y
40.4
Median 5Y
38.9
Industry
12.9
Forward
56.6
More Details
82.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
82.1
vs History
1
vs Industry
4
Median 3Y
51.9
Median 5Y
49.6
Industry
17.4
Forward
87.6
More Details
108.3
EV/OCF
EV/OCF
Enterprise Value to OCF
108.3
vs History
7
vs Industry
4
Median 3Y
60.1
Median 5Y
57.8
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-361.7
Median 5Y
-234.1
Industry
18.2
More Details
16.7
EV/IC
EV/IC
Enterprise Value to IC
16.7
vs History
1
vs Industry
6
Median 3Y
9.9
Median 5Y
9.3
Industry
1.9
More Details

Multiples Across Competitors

POLYMED Competitors Multiples
Poly Medicure Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Poly Medicure Ltd
NSE:POLYMED
286.3B INR 18.8 97.1 67.4 82.1
JP
Hoya Corp
TSE:7741
6.8T JPY 8.3 34.8 22.9 27.6
CH
Alcon AG
SIX:ALC
37.8B CHF 4.3 36 17.7 34.3
DK
Coloplast A/S
CSE:COLO B
175.9B DKK 6.5 34.8 22.4 26.4
US
Align Technology Inc
NASDAQ:ALGN
16.3B USD 4.1 37 18.7 22.5
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
52.2B CNY 11.8 28.2 24.5 24.5
KR
HLB Inc
KOSDAQ:028300
10.1T KRW 194.6 -54.4 -83.7 -79
US
Lantheus Holdings Inc
NASDAQ:LNTH
6.5B USD 4.4 15.3 10.5 11.9
CA
Bausch + Lomb Corp
NYSE:BLCO
6.4B USD 1.4 -17.3 16.7 55.9
UK
ConvaTec Group PLC
LSE:CTEC
4.5B GBP 2.6 37.1 266.5 465.5
US
Merit Medical Systems Inc
NASDAQ:MMSI
5.6B USD 4.2 46.6 23.2 38.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Poly Medicure Ltd
NSE:POLYMED
Average EV/EBITDA: 49.1
67.4
29%
2.3
JP
Hoya Corp
TSE:7741
22.9
15%
1.5
CH
Alcon AG
SIX:ALC
17.7
10%
1.8
DK
Coloplast A/S
CSE:COLO B
22.4
11%
2
US
Align Technology Inc
NASDAQ:ALGN
18.7
15%
1.2
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
24.5
27%
0.9
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -83.7 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
10.5
11%
1
CA
Bausch + Lomb Corp
NYSE:BLCO
16.7
22%
0.8
UK
ConvaTec Group PLC
LSE:CTEC
266.5
12%
22.2
US
Merit Medical Systems Inc
NASDAQ:MMSI
23.2
22%
1.1

See Also

Summary
POLYMED intrinsic value, competitors valuation, and company profile.
DCF Valuation
POLYMED stock valuation using Discount Cash Flow valuation method.
Relative Valuation
POLYMED stock valuation using valuation multiples.
Wall Street Estimates
POLYMED price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
POLYMED stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 214,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.